![Epstein–Barr Virus in Multiple Sclerosis: Theory and Emerging Immunotherapies: Trends in Molecular Medicine Epstein–Barr Virus in Multiple Sclerosis: Theory and Emerging Immunotherapies: Trends in Molecular Medicine](https://www.cell.com/cms/attachment/3d5690df-0de6-493c-8788-cf4d81073686/gr1_lrg.jpg)
Epstein–Barr Virus in Multiple Sclerosis: Theory and Emerging Immunotherapies: Trends in Molecular Medicine
![DNA immunotherapy targeting BARF1 induces potent anti-tumor responses against Epstein-Barr-virus-associated carcinomas - ScienceDirect DNA immunotherapy targeting BARF1 induces potent anti-tumor responses against Epstein-Barr-virus-associated carcinomas - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S2372770521001893-fx1.jpg)
DNA immunotherapy targeting BARF1 induces potent anti-tumor responses against Epstein-Barr-virus-associated carcinomas - ScienceDirect
![T-Cell Lymphomas Containing Epstein–Barr Viral DNA in Patients with Chronic Epstein–Barr Virus Infections | NEJM T-Cell Lymphomas Containing Epstein–Barr Viral DNA in Patients with Chronic Epstein–Barr Virus Infections | NEJM](https://www.nejm.org/na101/home/literatum/publisher/mms/journals/content/nejm/1988/nejm_1988.318.issue-12/nejm198803243181203/20130822/images/img_medium/nejm198803243181203_t2.jpeg)
T-Cell Lymphomas Containing Epstein–Barr Viral DNA in Patients with Chronic Epstein–Barr Virus Infections | NEJM
![Identification of Potential Inhibitors against Epstein–Barr Virus Nuclear Antigen 1 (EBNA1): An Insight from Docking and Molecular Dynamic Simulations | ACS Chemical Neuroscience Identification of Potential Inhibitors against Epstein–Barr Virus Nuclear Antigen 1 (EBNA1): An Insight from Docking and Molecular Dynamic Simulations | ACS Chemical Neuroscience](https://pubs.acs.org/cms/10.1021/acschemneuro.1c00350/asset/images/medium/cn1c00350_0006.gif)
Identification of Potential Inhibitors against Epstein–Barr Virus Nuclear Antigen 1 (EBNA1): An Insight from Docking and Molecular Dynamic Simulations | ACS Chemical Neuroscience
![Une nouvelle approche d'immunothérapie permet de rediriger les anticorps contre le virus d'Epstein-Barr vers des cellules responsables de maladies | Salle de presse | Inserm Une nouvelle approche d'immunothérapie permet de rediriger les anticorps contre le virus d'Epstein-Barr vers des cellules responsables de maladies | Salle de presse | Inserm](https://presse.inserm.fr/wp-content/uploads/2022/02/Illustration-466x482.png)